Drug
Ds1025a
Ds1025a: highest development phase Phase 1, developed by Daiichi Sankyo. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Daiichi Sankyo
Trials
| Drug | Phase | Indication |
|---|---|---|
| DS1025a NCT07681882 | Phase 1 | Advanced Solid Tumor |
Latest
No recent events.
Follow Ds1025a on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.